Insulin detemir versus insulin glargine for type 2 diabetes mellitus

Swinnen, S. G. H. A.; Simon, A. C. R.; Holleman, F.; Hoekstra, J. B. L.; DeVries, J. Hans

doi:10.1002/14651858.cd006383.pub2

Cited by 108 publications

(120 citation statements)

References 34 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Hypoglycaemia is a potent stimulus for energy intake and a plausible model for the weight‐sparing effects of insulin detemir, given the documented lower risk of hypoglycaemia with insulin detemir compared with human insulin 9; however, data from clinical trials comparing insulin detemir and insulin glargine show similar reductions in hypoglycaemia but show weight‐sparing only with insulin detemir 10. Moreover, Davies et al.…”

Section: Food Intake Modelmentioning

confidence: 99%

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?

Russell‐Jones

Danne

Hermansen

et al. 2015

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Insulin therapy is often associated with adverse weight gain. This is attributable, at least in part, to changes in energy balance and insulin's anabolic effects. Adverse weight gain increases the risk of poor macrovascular outcomes in people with diabetes and should therefore be mitigated if possible. Clinical studies have shown that insulin detemir, a basal insulin analogue, exerts a unique weight‐sparing effect compared with other basal insulins. To understand this property, several hypotheses have been proposed. These explore the interplay of efferent and afferent signals between the muscles, brain, liver, renal and adipose tissues in response to insulin detemir and comparator basal insulins. The following models have been proposed: insulin detemir may reduce food intake through direct or indirect effects on the central nervous system (CNS); it may have favourable actions on hepatic glucose metabolism through a selective effect on the liver, or it may influence fluid homeostasis through renal effects. Studies have consistently shown that insulin detemir reduces energy intake, and moreover, it is clear that this shift in energy balance is not a consequence of reduced hypoglycaemia. CNS effects may be mediated by direct action, by indirect stimulation by peripheral mediators and/or via a more physiological counter‐regulatory response to insulin through restoration of the hepatic–peripheral insulin gradient. Although the precise mechanism remains unclear, it is likely that the weight‐sparing effect of insulin detemir can be explained by a combination of mechanisms. The evidence for each hypothesis is considered in this review.

show abstract

Section: Food Intake Modelmentioning

confidence: 99%

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?

Russell‐Jones

Danne

Hermansen

et al. 2015

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Heise et al compared the pharmacokinetic profile of a single dose of s.c. NPH insulin, insulin glargine, and insulin detemir by the glucose-infusion rate (GIR) during a euglycemic clamp technique in patients with T1D. The authors reported the GIR of the first 12 h to be 27 and 44% higher for insulin detemir and NPH insulin, respectively, than that observed following insulin glargine (21,22). Circulating IGFBP1 originates from the liver and its synthesis is primarily regulated by insulin, whereas glucose as also shown in this study plays a minor role (23).…”

Section: Discussionmentioning

confidence: 99%

Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH–IGF1–IGFBP axis in patients with type 1 diabetes

Christiansen

Laursen

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Insulin regulates the GH-IGF1 axis. Insulin analogs differ from human insulin in receptor affinity and possibly liver accessibility. Therefore, we compared the GH-IGF1 axis response with human NPH insulin, insulin detemir, and insulin glargine in patients with type 1 diabetes (T1D). Methods: A total of 17 patients (seven were women) with T1D (age of 42 (24-63) 3) mg/l!h), but in the highest AUC of bioactive IGF (3.8 (3.5-4.2) vs 3.7 (3.4-4.0) vs 4.4 (4.1-4.8) mg/l!h) (all P!0.01). These differences were unrelated to plasma glucose. By contrast, profiles of total IGF1, IGFBP2, and IGFBP3 were comparable. Conclusions: Independent of plasma glucose, a single dose of detemir caused larger suppression in serum IGFBP1 than NPH and glargine, whereas bioactive IGF was higher, thereby explaining the lower GH levels. Thus, detemir appears to be more liver specific than NPH insulin and glargine.

show abstract

“…Estudios que comparan las dos primeras no han demostrado diferencias significativas entre ellas 45 . Ensayos clí-nicos en pacientes diabéticos con función renal normal sugieren que degludec tiene una efectividad similar a glargina en la disminución de la glucemia, con menor riesgo de producir hipoglucemia, lo que lo convierte en un medicamento muy útil para el control diabético 46-49 .…”

Section: Segundo Nivel De Atenciónunclassified

Lineamientos para el control de la glucemia y albuminuria en pacientes con nefropatía diabética en primer y segundo nivel de atención en Colombia. Panel nacional de expertos

Medina¹,

Sandoval-Salinas²,

Serrano³

et al. 2018

ALAD

View full text Add to dashboard Cite

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

Cited by 108 publications

References 34 publications

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?

Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH–IGF1–IGFBP axis in patients with type 1 diabetes

Lineamientos para el control de la glucemia y albuminuria en pacientes con nefropatía diabética en primer y segundo nivel de atención en Colombia. Panel nacional de expertos

Contact Info

Product

Resources

About